DYADIC INTERNATIONAL INC (DYAI)
US26745T1016 - Common Stock
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a...
Discovering Undervalued Stocks in Today’s Market: OCGN, INBS, KAVL, DYAI, VTAK
Exploring Stock Surges: Key Insights, Noteworthy BUZZ: KAVL, PRSO, DYAI, WISA, JAGX
DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q4 2023
DYAI stock results show that Dyadic International missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dyadic International (NASDAQ:DYAI) just reported results for the fourth quarter...
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from...
Dyadic Announces Change in Board and Management Leadership Roles
Dyadic Announces Change in Board and Management Leadership Roles
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a...
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
Dyadic to Attend Industry Events in April
Dyadic to Attend Industry Events in April
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared...
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global...
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
Dyadic International Inc. (NASDAQ: DYAI): A Value Play Gaining Investor Attention
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
Biotech Breakthroughs: Dyadic International (NASDAQ: DYAI) Partners with Rabian BV to Combat Rabies
Dyadic to Attend Industry Events in March
Dyadic to Attend Industry Events in March
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following industry events during the month of March 2024.
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”)...